Cover Image
市場調查報告書

記憶障礙:開發中產品分析

Memory Impairment - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 268983
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
記憶障礙:開發中產品分析 Memory Impairment - Pipeline Review, H2 2015
出版日期: 2015年09月30日 內容資訊: 英文 64 Pages
簡介

記憶障礙或記憶缺損的定義是在每天活動構成障礙的範圍內經常欠缺資訊記憶能力。其症狀為無法跟上與他人的對話、或是難以理解會話內容、重覆同樣的資訊,或是重覆同樣的問題等。發病的要素有酒精依存症、腦部受損、脫水症、憂鬱症、神經不安及緊張狀態等。

本報告提供記憶障礙治療藥的開發情形調查分析,提供開發中產品的概要,臨床實驗各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關系統性資訊。

簡介

  • 調查範圍

記憶障礙概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

記憶障礙:企業開發中的治療藥

記憶障礙:大學/機關研究中的治療藥

記憶障礙:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

記憶障礙:企業開發中的產品

記憶障礙:大學/機關研究中的產品

記憶障礙治療藥的開發企業

  • F. Hoffmann-La Roche Ltd.
  • Suven Life Sciences Ltd.
  • Met P Pharma AG
  • Dart NeuroScience LLC.
  • Omeros Corporation
  • Sunovion Pharmaceuticals Inc.
  • AbbVie Inc.

記憶障礙:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • HT-1067
  • pregnenolone succinate
  • levetiracetam
  • HT-3951
  • 2-PMPA
  • meldonium
  • AC-253
  • RO-4938581
  • SUN
  • A-582941
  • SUVN-91121
  • Antisense Oligonucleotide to Inhibit microRNA for Neurology
  • Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders
  • Small Molecules Targeting Galanin Receptor 3 for Memory Impairment and Depression
  • Small Molecules Targeting Phosphodiesterase 4 for Memory Impairment
  • Drug to Activate Lipoprotein Lipase for Obesity and Brain disorders
  • Adult Stem Cells
  • Bryostatin Analogues
  • Learning and Memory Program
  • Drug for Memory Impairment

記憶障礙:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6978IDB

Summary

Global Markets Direct's, 'Memory Impairment - Pipeline Review, H2 2015', provides an overview of the Memory Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Memory Impairment
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Memory Impairment
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Memory Impairment Overview
  • Therapeutics Development
    • Pipeline Products for Memory Impairment - Overview
    • Pipeline Products for Memory Impairment - Comparative Analysis
  • Memory Impairment - Therapeutics under Development by Companies
  • Memory Impairment - Therapeutics under Investigation by Universities/Institutes
  • Memory Impairment - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Memory Impairment - Products under Development by Companies
  • Memory Impairment - Products under Investigation by Universities/Institutes
  • Memory Impairment - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Calico LLC
    • M et P Pharma AG
    • Neuren Pharmaceuticals Limited
    • Omeros Corporation
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
  • Memory Impairment - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-988315 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AC-253 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dehydroevodiamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-0712 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HT-3951 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NNZ-2591 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P7-C3A20 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pregnenolone succinate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • roflumilast - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 to Inhibit PDE4 for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 to Inhibit PDE4 for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Carbonic Anhydrase for Learning and Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit MAO-B for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate PKC for CNS and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize GALR3 for Memory Impairment - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Memory Impairment - Recent Pipeline Updates
  • Memory Impairment - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Memory Impairment, H2 2015
  • Number of Products under Development for Memory Impairment - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Memory Impairment - Pipeline by AbbVie Inc., H2 2015
  • Memory Impairment - Pipeline by Calico LLC, H2 2015
  • Memory Impairment - Pipeline by M et P Pharma AG, H2 2015
  • Memory Impairment - Pipeline by Neuren Pharmaceuticals Limited, H2 2015
  • Memory Impairment - Pipeline by Omeros Corporation, H2 2015
  • Memory Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015
  • Memory Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Memory Impairment Therapeutics - Recent Pipeline Updates, H2 2015
  • Memory Impairment - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Memory Impairment, H2 2015
  • Number of Products under Development for Memory Impairment - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top